Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial

被引:144
|
作者
Naslund, Ulf [1 ,2 ]
Ng, Nawi [3 ]
Lundgren, Anna [3 ]
Fharm, Eva [4 ]
Gronlund, Christer [7 ]
Johansson, Helene [3 ]
Lindahl, Bernt [10 ,11 ]
Lindahl, Bertil [5 ]
Lindvall, Kristina [3 ]
Nilsson, Stefan K. [8 ]
Nordin, Maria [9 ]
Nordin, Steven [9 ]
Nyman, Emma [1 ,2 ]
Rocklov, Joacim [5 ]
Vanoli, Davide [1 ,2 ]
Weinehall, Lars [3 ]
Wennberg, Patrik [4 ]
Wester, Per [6 ]
Norberg, Margareta [3 ]
机构
[1] Umea Univ, Heart Ctr, Umea, Sweden
[2] Umea Univ, Dept Publ Hlth & Clin Med, S-90187 Umea, Sweden
[3] Umea Univ, Unit Epidemiol & Global Hlth, Umea, Sweden
[4] Umea Univ, Unit Family Med, Umea, Sweden
[5] Umea Univ, Unit Occupat & Environm Med, Umea, Sweden
[6] Umea Univ, Unit Med, Umea, Sweden
[7] Umea Univ, Dept Publ Hlth & Clin Med, Dept Radiat Sci, Umea, Sweden
[8] Umea Univ, Unit Physiol Chem, Dept Med Biosci, Umea, Sweden
[9] Umea Univ, Dept Psychol, Umea, Sweden
[10] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[11] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
来源
LANCET | 2019年 / 393卷 / 10167期
基金
瑞典研究理事会;
关键词
INTIMA-MEDIA THICKNESS; EUROPEAN STROKE CONFERENCES; LIFE-STYLE; ADVISORY BOARD; RISK-FACTORS; ADHERENCE; MANNHEIM; BRUSSELS; BELGIUM; SOCIETY;
D O I
10.1016/S0140-6736(18)32818-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Primary prevention of cardiovascular disease often fails because of poor adherence among practitioners and individuals to prevention guidelines. We aimed to investigate whether ultrasound-based pictorial information about subclinical carotid atherosclerosis, targeting both primary care physicians and individuals, improves prevention. Methods Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA) is a pragmatic, open-label, randomised controlled trial that was integrated within the Vasterbotten Intervention Programme, an ongoing population-based cardiovascular disease prevention programme in northern Sweden. Individuals aged 40, 50, or 60 years with one or more conventional risk factors were eligible to participate. Participants underwent clinical examination, blood sampling, and ultrasound assessment of carotid intima media wall thickness and plaque formation. Participants were randomly assigned 1: 1 with a computer-generated randomisation list to an intervention group (pictorial representation of carotid ultrasound plus a nurse phone call to confirm understanding) or a control group (not informed). The primary outcomes, Framingham risk score (FRS) and European systematic coronary risk evaluation (SCORE), were assessed after 1 year among participants who were followed up. This study is registered with ClinicalTrials.gov, number NCT01849575. Findings 3532 individuals were enrolled between April 29, 2013, and June 7, 2016, of which 1783 were randomly assigned to the control group and 1749 were assigned to the intervention group. 3175 participants completed the 1-year follow-up. At the 1-year follow-up, FRS and SCORE differed significantly between groups (FRS 1.07 [95% CI 0.11 to 2.03, p=0.0017] and SCORE 0.16 [0.02 to 0.30, p=0.0010]). FRS decreased from baseline to the 1-year follow-up in the intervention group and increased in the control group (-0.58 [95% CI -0.86 to -0.30] vs 0.35 [0.08 to 0.63]). SCORE increased in both groups (0.13 [95% CI 0.09 to 0.18] vs 0.27 [0.23 to 0.30]). Interpretation This study provides evidence of the contributory role of pictorial presentation of silent atherosclerosis for prevention of cardiovascular disease. It supports further development of methods to reduce the major problem of low adherence to medication and lifestyle modification. Copyright (c) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:133 / 142
页数:10
相关论文
共 50 条
  • [21] Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial
    Wang, Min
    Li, Dewei
    Chen, Rufu
    Huang, Xiaobing
    Li, Jing
    Liu, Yahui
    Liu, Jianhua
    Cheng, Wei
    Chen, Xuemin
    Zhao, Wenxing
    Li, Jingdong
    Tan, Zhijian
    Huang, Heguang
    Li, Deyu
    Zhu, Feng
    Qin, Tingting
    Ma, Jingdong
    Yu, Guangsheng
    Zhou, Baoyong
    Zheng, Shangyou
    Tang, Yichen
    Han, Wei
    Meng, Lingyu
    Ke, Jianji
    Feng, Feng
    Chen, Botao
    Yin, Xinmin
    Chen, Weibo
    Ma, Hongqin
    Xu, Jian
    Liu, Yifeng
    Lin, Ronggui
    Dong, Yadong
    Yu, Yahong
    Liu, Jun
    Zhang, Hang
    Qin, Renyi
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (06): : 438 - 447
  • [22] Yoga therapy on elderly patients with fear of fall: an open-label randomised controlled trial (YOFEAR trial)
    Kashyap, Kritartha
    Dhar, Minakshi
    Bisht, Khushboo
    Bahurupi, Yogesh
    Pathania, Monika
    BMJ OPEN, 2023, 13 (12):
  • [23] Secondary prevention of stroke by a primary health care approach: An open-label cluster randomised trial
    Sylaja, P. N.
    Singh, Gurpreet
    Sivasambath, S.
    Arun, K.
    Jeemon, Panniyammakal
    Antony, Roni
    Kalani, Rizwan
    Gopal, Bipin K.
    Soman, Biju
    JOURNAL OF CLINICAL NEUROSCIENCE, 2021, 84 : 53 - 59
  • [24] Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
    不详
    LANCET NEUROLOGY, 2008, 7 (01): : 41 - 49
  • [25] Re: The Preventive Antibiotics in Stroke Study (PASS): A Pragmatic Randomised Open-Label Masked Endpoint Clinical Trial
    Schaeffer, Edward M.
    JOURNAL OF UROLOGY, 2016, 195 (02): : 369 - 369
  • [26] A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial
    Van Linschoten, R.
    Jansen, F.
    Pauwels, R.
    Smits, L.
    Atsma, F.
    Kievit, W.
    de Jong, D.
    de Vries, A.
    Boekema, P.
    West, R.
    Bodelier, A.
    Gisbertz, I.
    Wolfhagen, F.
    Romkens, T.
    Lutgens, M.
    van Bodegraven, A.
    Oldenburg, B.
    Pierik, M.
    Russel, M.
    de Boer, N.
    Mallant-Hent, R.
    ter Borg, P.
    van der Meulen-de Jong, A.
    Jansen, J.
    Jansen, S.
    Tan, A.
    van der Woude, C. J.
    Hoentjen, F.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 655 - 658
  • [27] Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson's Disease: An Open-Label, Pragmatic Trial
    Kim, Aryun
    Kim, Young Eun
    Yun, Ji Young
    Kim, Han-Joon
    Yang, Hui-Jun
    Lee, Woong-Woo
    Shin, Chae Won
    Park, Hyeyoung
    Jung, Yu Jin
    Kim, Ahro
    Kim, Yoon
    Jang, Mihee
    Jeon, Beomseok
    JOURNAL OF MOVEMENT DISORDERS, 2018, 11 (02) : 65 - 71
  • [28] Monitoring patients with acute dyspnoea with a serial focused ultrasound of the heart and the lungs (MODUS): a protocol for a multicentre, randomised, open-label, pragmatic and controlled trial
    Arvig, Michael D.
    Lassen, Annmarie T.
    Gaede, Peter H.
    Laursen, Christian B.
    BMJ OPEN, 2020, 10 (06): : e034373
  • [29] Effectiveness, usability and acceptability of a smart inhaler programme in patients with asthma: protocol of the multicentre, pragmatic, open-label, cluster randomised controlled ACCEPTANCE trial
    van de Hei, Susanne J.
    Poot, Charlotte C.
    van den Berg, Liselot N.
    Meijer, Eline
    van Boven, Job F. M.
    Flokstra-de Blok, Bertine M. J.
    Postma, Maarten J.
    Chavannes, Niels H.
    Kocks, Janwillem W. H.
    BMJ OPEN RESPIRATORY RESEARCH, 2022, 9 (01)
  • [30] Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD): an open-label pragmatic feasibility randomised controlled trial
    Subhani, Mohsan
    Enki, Doyo G.
    Knight, Holly
    Jones, Katy A.
    Sprange, Kirsty
    Rennick-Egglestone, Stefan
    Morling, Joanne R.
    Wragg, Andrew
    Hutton, Clare
    Ryder, Stephen D.
    ECLINICALMEDICINE, 2023, 61